Trial · NCT01074294
Participant flow32
How many started, completed or left each group, period by period.
1 to 20 of 32
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase A (Day 1 to Week 5) | STARTED | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 740 | |
| Phase A (Day 1 to Week 5) | STARTED | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | STARTED | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | STARTED | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | Analyzed for Safety | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 733 | |
| Phase A (Day 1 to Week 5) | Analyzed for Safety | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | Analyzed for Safety | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | Analyzed for Safety | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | COMPLETED | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 574 | |
| Phase A (Day 1 to Week 5) | COMPLETED | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | COMPLETED | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | COMPLETED | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | NOT COMPLETED | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 166 | |
| Phase A (Day 1 to Week 5) | NOT COMPLETED | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | NOT COMPLETED | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 0 | |
| Phase A (Day 1 to Week 5) | NOT COMPLETED | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | |
| Phase B and Phase A+ (Week 6 to Week 11) | STARTED | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 0 | |
| Phase B and Phase A+ (Week 6 to Week 11) | STARTED | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 155 | |
| Phase B and Phase A+ (Week 6 to Week 11) | STARTED | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 80 | |
| Phase B and Phase A+ (Week 6 to Week 11) | STARTED | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 339 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01074294/flow